Safety profile of treatment in diabetic peripheral neuropathic pain

Research output: Contribution to journalReview articlepeer-review

12 Scopus citations


New treatment options for diabetic peripheral neuropathic pain (DPNP) have recently been developed, including two Food and Drug Administration (FDA) approved agents, duloxetine and pregabalin. As clinicians face a broader spectrum of efficacious treatments, side-effect profiles play an increasingly important role in the development of a pain management regimen. In this article we review the safety profile of agents commonly used in the treatment of DPNP.

Original languageEnglish
Pages (from-to)S43-S49
JournalPain Medicine
Issue numberSUPPL. 2
StatePublished - Sep 2007


  • Diabetic Neuropathy
  • Neuropathic Pain
  • Safety/Tolerability


Dive into the research topics of 'Safety profile of treatment in diabetic peripheral neuropathic pain'. Together they form a unique fingerprint.

Cite this